Table 2.

Summary of the heavy chain CDR3 (HCDR3) sequences used for CDR grafting in this work. The HCDR3 sequences from clinical-stage antibodies possess differences in net charge and sequence composition consisting of negatively charged (red), positively charged (blue), hydrophobic (green) and polar (black) residues. The net charges of the HCDR3 and Fv regions (pH 7.4) are calculated as described in Table 1. The muromonab HCDR3 contains a cysteine that was mutated to serine in this study.

HCDR3 #	HCDR3 amino acid sequences										Origin of HCDR3	HCDR3 net charge (pH 6)	HCDR3 net charge (pH 7.4)	Fv net charge of variants (pH 7.4)
														hOKT3	Tras.	Silt.	Lebr.
1	Y	D	G	I	Y	G	E	L	D	F	Carlumab	−3	−3	9.1	2.2	−2	−2.9
2	Y	Y	D	D	H	Y	S	L	D	Y	Muromonab*	−2.5	−2.9	9.2	2.3	−1.9	−2.8
3	G	G	D	G	F	Y	A	M	D	Y	Trastuzumab	−2	−2	10.1	3.2	−1	−1.9
4	Y	D	H	Y	S	G	S	S	D	Y	Bapineuzumab	−1.5	−1.9	10.2	3.3	−0.9	−1.8
5	H	G	D	D	P	A	W	F	A	Y	Farletuzumab	−1.5	−1.9	10.2	3.3	−0.9	−1.8
6	G	L	K	M	A	T	I	F	D	Y	Seribantumab	0	0	12.1	5.2	1	0.1
7	S	L	A	R	T	T	A	M	D	Y	Tocilizumab	0	0	12.1	5.2	1	0.1
8	H	R	S	G	Y	F	S	M	D	Y	Girentuximab	0.5	0.1	12.2	5.3	1.1	0.2
9	R	Q	R	F	P	Y	Y	F	D	Y	Lenzilumab	1	1	13.1	6.2	2	1.1
10	R	R	P	G	Q	G	Y	F	D	F	Ustekinumab	1	1	13.1	6.2	2	1.1